Ocugen Stock Price

0.13 (4.85%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 5,784,196
Bid Price 2.79
Ask Price 2.81
News (1)
Day High 2.875


52 Week Range


Day Low 2.697
Company Name Stock Ticker Symbol Market Type
Ocugen Inc OCGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.13 4.85% 2.81 19:59:24
Open Price Low Price High Price Close Price Prev Close
2.75 2.697 2.875 2.84 2.68
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
15,531 5,784,196 $ 2.82 $ 16,312,745 - 1.67 - 17.65
Last Trade Time Type Quantity Stock Price Currency
19:59:53 formt 500 $ 2.81 USD


Draw Mode:

Ocugen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 606.01M 215.66M 157.92M $ - $ - -0.29 -8.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 2.23M 1.40%

more financials information »

Ocugen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OCGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.732.952.572.775,819,3040.082.93%
1 Month2.712.952.332.655,040,8250.103.69%
3 Months2.283.111.862.456,109,6950.5323.25%
6 Months3.804.531.672.858,562,657-0.99-26.05%
1 Year7.6817.651.677.0815,381,271-4.87-63.41%
3 Years3.2418.770.176.0525,057,617-0.43-13.27%
5 Years3.2418.770.176.0525,057,617-0.43-13.27%

Ocugen Description

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now